60 Degrees Yields Right of Reference to NDA in Support of Phase IIb Study

 

• University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria.
• SJ733 will be combined with a single dose of tafenoquine in the study.
• The right of reference allows FDA to review 60 Degrees Pharma’s regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program.

https://www.globenewswire.com/news-release/2024/08/12/2928485/0/en/60-Degrees-Pharma-Provides-University-of-Kentucky-with-Right-of-Reference-to-ARAKODA-NDA-in-Support-of-SJ733-Phase-IIb-Study.html